Stay ahead in oncology diagnostics with a thorough course on the FDA’s proposed rule to reclassify immunohistochemistry (IHC) test systems used alongside approved oncology therapeutics. Gain detailed insights into the new regulatory landscape, covering the rationale for moving from class III (premarket approval) to class II (special controls), affected device codes, identified risks, and new expectations for performance data and labeling. This course prepares you for regulatory compliance, clinical implementation, and effective stakeholder participation in shaping future requirements.
In this course you will learn the following:
* Understand the purpose and intent of the proposed reclassification.
* Describe the regulatory framework for medical device classification.
* Identify the scope and types of IHC test systems affected.
* Recognize the risks and benefits associated with these devices.
* Explain the proposed special controls and their role in ensuring safety and effectiveness.
* Navigate the public comment process and understand the importance of stakeholder engagement.
* Appreciate that the rule is not final and may change based on public input.



